Managing Insomnia in Patients Taking Auvelity
If insomnia develops while taking Auvelity, first adjust the timing of the medication by taking the second dose earlier in the day (no later than early afternoon) rather than adding a separate sleep medication, as insomnia is a recognized adverse effect of the bupropion component. 1, 2
Understanding the Problem
Insomnia is one of the most common adverse effects of Auvelity, occurring frequently enough to be listed among the primary side effects in the FDA labeling 2. This is primarily attributable to the bupropion component, which is known to cause insomnia as a dose-dependent adverse effect 3. The dextromethorphan component can also contribute through somnolence during the day (which may disrupt nighttime sleep architecture) and general CNS activation 1.
Step-by-Step Management Algorithm
Step 1: Timing Optimization (First-Line)
- Move the second daily dose earlier: Take the second dose no later than 1-2 PM to minimize evening stimulation
- Maintain the morning dose timing: Keep the first dose in the early morning
- This simple intervention often resolves medication-induced insomnia without requiring additional pharmacotherapy 3
Step 2: Sleep Hygiene Reinforcement
While not adding medications yet, ensure:
- No caffeine after noon
- Regular sleep-wake schedule
- Dark, cool sleeping environment
- No screens 1 hour before bed
Step 3: If Insomnia Persists - Pharmacologic Options
When pharmacotherapy becomes necessary, the evidence supports specific choices:
Preferred Options (Based on Guidelines):
- Eszopiclone, zolpidem, or suvorexant show the best evidence for short-term efficacy in insomnia disorder 4
- These are FDA-approved specifically for insomnia and have established safety profiles
- Critical caveat: Use the lowest effective dose, particularly in women and older adults, due to FDA warnings about cognitive impairment and driving risks 4
Important Drug Interaction Considerations:
Auvelity has significant CYP2D6 inhibition 1. This means:
- Avoid medications requiring CYP2D6 metabolism for activation
- Use caution with any sedative-hypnotic that is a CYP2D6 substrate
- Monitor closely for enhanced sedation if combining with any CNS depressants
Step 4: What NOT to Use
Avoid these options:
- Sedating antidepressants (e.g., trazodone, mirtazapine): Insufficient evidence for efficacy in insomnia 5, and adding another antidepressant to Auvelity increases serotonin syndrome risk 1
- Antihistamines (diphenhydramine): While effective for acute insomnia 6, the anticholinergic burden combined with Auvelity's CNS effects is problematic
- Benzodiazepines: Higher risk profile in general use, particularly concerning for falls, cognitive impairment, and dependence 4
- Alcohol: Explicitly contraindicated with Auvelity due to increased neuropsychiatric events 1
Critical Safety Monitoring
Watch for these red flags that require immediate intervention:
- Worsening agitation or restlessness (may indicate serotonin syndrome if combined with wrong medication) 1
- Daytime somnolence severe enough to impair function (dextromethorphan effect) 1
- Any seizure activity (bupropion lowers seizure threshold; sleep deprivation further increases risk) 1
When to Reconsider Auvelity Entirely
If insomnia remains severe and refractory despite timing adjustments and appropriate hypnotic therapy, the risk-benefit ratio of continuing Auvelity should be reassessed. Chronic insomnia itself significantly impairs quality of life and can worsen depression 5, potentially negating the antidepressant benefits of Auvelity.
Evidence Quality Note
The insomnia pharmacotherapy guidelines 4, 5 emphasize that most evidence for sleep medications is short-term (weeks to months), yet insomnia is often chronic. The FDA labeling for Auvelity 1, 2 clearly identifies insomnia as a common adverse effect but provides no specific guidance on management beyond general monitoring. This creates a clinical gap where practical judgment must prevail: prioritize non-pharmacologic timing adjustments first, use evidence-based hypnotics cautiously when needed, and avoid polypharmacy that increases interaction risks.